Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ITGA4 | P13612 | 16/20 | 0.45 |
| ▸ | ITGB1 | P05556 | 14/20 | 0.45 |
| ▸ | ITGB7 | P26010 | 9/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | KIFC1 | Q9BW19 | 1/20 | 0.41 |
| ▸ | PDK1 | Q15118 | 1/20 | 0.41 |
| ▸ | PDK2 | Q15119 | 1/20 | 0.41 |
| ▸ | PDK3 | Q15120 | 1/20 | 0.41 |
| ▸ | PDK4 | Q16654 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5926662 | 0.93 | ITGA4 (0.46) | ITGA4ITGB1ITGB7 | |
| SCHEMBL5927573 | 0.93 | ITGA4 (0.45) | ITGA4ITGB1ITGB7KIFC1 | |
| SCHEMBL3995536 | 0.92 | KIFC1 (0.48) | ITGA4ITGB1ITGB7KIFC1PDK1 | |
| SCHEMBL5926194 | 0.92 | ITGA4 (0.46) | ITGA4ITGB1ITGB7 | |
| SCHEMBL5927210 | 0.91 | ITGA4 (0.45) | ITGA4ITGB1ITGB7KMT2AKIFC1 | |
| SCHEMBL5926197 | 0.91 | SERPINE1 (0.49) | ITGA4ITGB1ITGB7KIFC1PDK1 | |
| SCHEMBL3998542 | 0.91 | ITGA4 (0.48) | ITGA4ITGB1ITGB7 | |
| SCHEMBL3992357 | 0.90 | ITGA4 (0.44) | ITGA4ITGB1ITGB7 | |
| SCHEMBL3999068 | 0.90 | ITGA4 (0.44) | ITGA4ITGB1ITGB7 | |
| SCHEMBL8337057 | 0.90 | ITGA4 (0.43) | ITGA4ITGB1ITGB7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7544699-B2 | Aryl and heteroaryl compounds, compositions, and methods of use | TRANSTECH PHARMA, INC. (US) | 2009-06-09 | — | — | US | disclosed |
| US-7544699-B2 | Aryl and heteroaryl compounds, compositions, and methods of use | TRANSTECH PHARMA, INC. (US) | 2009-06-09 | — | — | US | disclosed |
| US-7544699-B2 | Aryl and heteroaryl compounds, compositions, and methods of use | TRANSTECH PHARMA, INC. (US) | 2009-06-09 | — | — | US | disclosed |
| US-20060276518-A1 | Aryl and heteroaryl compounds and methods to modulate coagulation | TRANSTECH PHARMA, INC. | 2006-12-07 | — | — | US | disclosed |
| US-7122580-B2 | Aryl and heteroaryl compounds and methods to modulate coagulation | TRANSTECH PHARMA, INC. (US) | 2006-10-17 | — | — | US | disclosed |
| US-20050059705-A1 | Aryl and heteroaryl compounds, compositions, and methods of use | VTVX HOLDINGS I LLC | 2005-03-17 | — | — | US | disclosed |
| WO-2005014533-A2 | ARYL AND HETEROARYL COMPOUNDS, COMPOSITIONS, AND METHODS OF USE | TRANSTECH PHARMA, INC. (US) | 2005-02-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060276518-A1 | Aryl and heteroaryl compounds and methods to modulate coagulation | TFPI, F9, F2 | ITGA4 312/4885ITGB1 240/4885ITGB7 762/4885 |
| US-20050059705-A1 | Aryl and heteroaryl compounds, compositions, and methods of use | TFPI, F3, F2 | ITGA4 1170/4885ITGB1 826/4885ITGB7 926/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.